Anthera Pharmaceuticals (ANTH) Lifted to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Anthera Pharmaceuticals (NASDAQ:ANTH) from a hold rating to a buy rating in a research note issued to investors on Tuesday. They currently have $2.75 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
A number of other equities analysts have also weighed in on ANTH. ValuEngine raised Anthera Pharmaceuticals from a strong sell rating to a sell rating in a research report on Sunday, December 31st. Roth Capital started coverage on Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They issued a buy rating and a $10.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Anthera Pharmaceuticals currently has an average rating of Hold and a consensus price target of $4.38.
Large investors have recently modified their holdings of the business. Wedbush Securities Inc. raised its position in Anthera Pharmaceuticals by 75.8% in the 3rd quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 31,800 shares during the last quarter. 683 Capital Management LLC purchased a new position in Anthera Pharmaceuticals in the 4th quarter worth about $399,000. BVF Inc. IL raised its position in Anthera Pharmaceuticals by 20.9% in the 4th quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock worth $2,007,000 after buying an additional 209,896 shares during the last quarter. Finally, Armistice Capital LLC purchased a new position in Anthera Pharmaceuticals in the 4th quarter worth about $1,269,000. 16.44% of the stock is owned by institutional investors and hedge funds.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.